Common use of Research Activity Clause in Contracts

Research Activity. During each of Collaboration Years 5 and 6 of the Research Period, and subject to Monsanto’s timely [* * *], Evogene shall commence conducting no less than the minimum number of G2P Optimization Rounds for such Collaboration Year, under the Funded Project, each in respect of not less than the minimum number of Collaboration Hit Homolog and/or Special Collaboration Hits that shall enter such G2P Optimization Round, as set forth in subsections (a) and (b) below: (a) During Collaboration Year 5, a minimum of one (1) G2P Optimization Round for a minimum of [* * *] ([* * *]) Collaboration Hit Homologs and/or Special Collaboration Hits which shall enter such G2P Optimization Round. (b) During Collaboration Year 6, a minimum of one (1) G2P Optimization Round for a minimum of [* * *] ([* * *]) Collaboration Hit Homologs and/or Special Collaboration Hits which shall enter such G2P Optimization Round. *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission.

Research Activity. During each of Collaboration Years 4 and 5 and 6 of the Research Period, Period and subject to Monsanto’s timely [* * *]provision to Evogene of the report set forth in Section 5.8, Evogene shall commence conducting no not less than the minimum number of G2P Optimization Enhancement Rounds for such Collaboration Year, under the Funded Project, each in respect of not less than the a minimum number of Collaboration Hit Homolog and/or Special Collaboration Hits Homologs that shall enter such G2P Optimization Enhancement Round, as set forth in subsections Subsections (a) and (b) below: (a) During Collaboration Year 5, a minimum of one (1) G2P Optimization Round for a minimum of [* * *] ([* * *]) Collaboration Hit Homologs and/or Special Collaboration Hits which shall enter such G2P Optimization Round. (b) During Collaboration Year 6, a minimum of one (1) G2P Optimization Round for a minimum of [* * *] ([* * *]) Collaboration Hit Homologs and/or Special Collaboration Hits which shall enter such G2P Optimization Round. : *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. (a) During Collaboration Year 4, a minimum of [* * *] ([* * *]) G2P Enhancement Rounds, in respect of a total of [* * *] ([* * *]) Collaboration Hit Homologs, from Collaboration Hits previously discovered by Evogene, which shall enter such G2P Enhancement Round. (b) During Collaboration Year 5, a minimum of [* * *] ([* * *]) G2P Enhancement Rounds in respect of a total of [* * *] ([* * *]) Collaboration Hit Homologs from Gene Group 6 which shall enter such G2P Enhancement Round.

Research Activity. During each of Collaboration Years 4 and 5 and 6 of the Research Period, Period and subject to Monsanto’s timely [* * *]provision to Evogene of the report set forth in Section 5.5E, Evogene shall commence conducting no not less than the minimum number of G2P Optimization Enhancement Rounds for such Collaboration Year, under the Funded Project, each in respect of not less than the a minimum number of Collaboration Hit Homolog and/or Special Collaboration Hits Homologs that shall enter such G2P Optimization Enhancement Round, as set forth in subsections Subsections (a) and (b) below: (a) During Collaboration Year 4, a minimum of [* * *] ([* * *]) G2P Enhancement Rounds, in respect of a total of [* * *] ([* * *]) Collaboration Hit Homologs, from Collaboration Hits previously discovered by Evogene, which shall enter such G2P Enhancement Round. (b) During Collaboration Year 5, a minimum of one [* * *] (1[* * *]) G2P Optimization Round for Enhancement Rounds in respect of a minimum total of [* * *] ([* * *]) Collaboration Hit Homologs and/or Special Collaboration Hits from Gene Group 6 which shall enter such G2P Optimization Enhancement Round. (b) During Collaboration Year 6, a minimum of one (1) G2P Optimization Round for a minimum of [* * *] ([* * *]) Collaboration Hit Homologs and/or Special Collaboration Hits which shall enter such G2P Optimization Round. *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission.